时钟基因Period家族在头颈鳞状细胞癌中的研究进展

doi:10.3760/cma.j.cn371439-20240927-00017

国际肿瘤学杂志 ›› 2025, Vol. 52 ›› Issue (2): 113-118.doi: 10.3760/cma.j.cn371439-20240927-00017

时钟基因Period家族在头颈鳞状细胞癌中的研究进展

叶永英¹, 邹艳¹, 陈天明¹, 吴伟莉¹^,²^,³()

¹贵州医科大学临床医学院肿瘤学教研室，贵阳 550000
²贵州医科大学附属肿瘤医院肿瘤科，贵阳 550000
³贵州医科大学附属医院肿瘤科，贵阳 550000

收稿日期:2024-09-27 修回日期:2024-12-08 出版日期:2025-02-08 发布日期:2025-03-17
通讯作者: 吴伟莉 E-mail:wwlmhy@163.com
基金资助:
国家自然科学基金(82060555);贵州省科技计划(Qiankehe Foundation-ZK [2024] General 208)

Research progress of clock gene Period family in head and neck squamous cell carcinoma

Ye Yongying¹, Zou Yan¹, Chen Tianming¹, Wu Weili¹^,²^,³()

¹Department of Oncology， School of Clinical Medicine， Guizhou Medical University， Guiyang 550000， China
²Department of Oncology， Affiliated Tumor Hospital of Guizhou Medical University， Guiyang 550000， China
³Department of Oncology， Affiliated Hospital of Guizhou Medical University， Guiyang 550000， China

Received:2024-09-27 Revised:2024-12-08 Online:2025-02-08 Published:2025-03-17
Contact: Wu Weili E-mail:wwlmhy@163.com
Supported by:
National Natural Science Foundation of China(82060555);Guizhou Provincial Science and Technology Program(Qiankehe Foundation-ZK [2024] General 208)

摘要/Abstract

摘要：

头颈鳞状细胞癌（HNSCC）是最常见的一类异质性恶性肿瘤。超过60%的HNSCC患者在确诊时已处于局部晚期，尽管先进的诊疗措施不断出现，但复发性或转移性HNSCC患者预后仍不理想。Period（PER）基因家族是生物钟基因的重要成员，其家族成员PER1、PER2、PER3在HNSCC中差异表达，参与肿瘤细胞的增殖、凋亡、侵袭或转移等生物学过程，多数研究中表现为抑癌作用，与肿瘤微环境及免疫治疗、时辰化疗等密切相关，是有潜在价值的生物标志物。综合分析PER基因家族在HNSCC中的表达及其在肿瘤的发生发展中发挥的生物学作用与相应分子生物学机制，有助于挖掘其在HNSCC诊断及治疗中的潜在应用价值。

关键词: 头颈鳞癌, 预后, 分子靶向治疗, 肿瘤微环境, Period基因

Abstract:

Head and neck squamous cell carcinoma （HNSCC） is the most common type of heterogeneous malignant tumor. Over 60% of HNSCC patients are at locally advanced stage at the time of diagnosis. Despite the emergence of advanced diagnosis and treatment measures， the prognosis of patients with recurrent or metastatic HNSCC remains poor. The Period （PER） gene family is an important member of the circadian clock genes， with family members PER1， PER2， and PER3 showing differential expression in HNSCC， participating in biological processes such as proliferation， apoptosis， invasion， or metastasis of tumor cells. In most studies， they exhibit anti-cancer effects and are closely related to the tumor microenvironment， immunotherapy， chronotherapy， etc.， making them potential biomarkers. A comprehensive analysis of the expression of PER gene family in HNSCC， its biological role in the occurrence and development of tumor and the corresponding molecular biological mechanism is helpful to explore its potential application value in the diagnosis and treatment of HNSCC.

Key words: Squamous cell carcinoma of head and neck, Prognosis, Molecular targeted therapy, Tumor microenvironment, Period gene

叶永英, 邹艳, 陈天明, 吴伟莉. 时钟基因Period家族在头颈鳞状细胞癌中的研究进展[J]. 国际肿瘤学杂志, 2025, 52(2): 113-118.

Ye Yongying, Zou Yan, Chen Tianming, Wu Weili. Research progress of clock gene Period family in head and neck squamous cell carcinoma[J]. Journal of International Oncology, 2025, 52(2): 113-118.

参考文献 43

[1]	Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024[J]. CA Cancer J Clin, 2024, 74(1): 12-49. DOI: 10.3322/caac.21820.
[2]	Mody MD, Rocco JW, Yom SS, et al. Head and neck cancer[J]. Lancet, 2021, 398(10318): 2289-2299. DOI: 10.1016/S0140-6736(21)01550-6.
[3]	Chen K, Wang Y, Li D, et al. Biological clock regulation by the PER gene family: a new perspective on tumor development[J]. Front Cell Dev Biol, 2024, 12: 1332506. DOI: 10.3389/fcell.2024.1332506.
[4]	Wang Q, Liu H, Wang Z, et al. Circadian gene Per3 promotes astroblastoma progression through the P53/BCL2/BAX signalling pathway[J]. Gene, 2024, 895: 147978. DOI: 10.1016/j.gene.2023.147978.
[5]	Rodríguez-Santana C, López-Rodríguez A, Martinez-Ruiz L, et al. The relationship between clock genes, sirtuin 1, and mitochondrial activity in head and neck squamous cell cancer: effects of melatonin treatment[J]. Int J Mol Sci, 2023, 24(19): 15030. DOI: 10.3390/ijms241915030.
[6]	He L, Ping F, Fan Z, et al. Salivary exosomal miR-24-3p serves as a potential detective biomarker for oral squamous cell carcinoma screening[J]. Biomed Pharmacother, 2020, 121: 109553. DOI: 10.1016/j.biopha.2019.109553. pmid: 31704611
[7]	Li YY, Jin F, Zhou JJ, et al. Downregulation of the circadian period family genes is positively correlated with poor head and neck squamous cell carcinoma prognosis[J]. Chronobiol Int, 2019, 36(12): 1723-1732. DOI: 10.1080/07420528.2019.1648486.
[8]	Aye L, Wang Z, Chen F, et al. Circadian regulator-mediated molecular subtypes depict the features of tumor microenvironment and indicate prognosis in head and neck squamous cell carcinoma[J]. J Immunol Res, 2023, 2023: 9946911. DOI: 10.1155/2023/9946911.
[9]	Gong X, Tang H, Yang K. PER1 suppresses glycolysis and cell proliferation in oral squamous cell carcinoma via the PER1/RACK1/PI3K signaling complex[J]. Cell Death Dis, 2021, 12(3): 276. DOI: 10.1038/s41419-021-03563-5. pmid: 33723221
[10]	Zhang J, Lv H, Ji M, et al. Low circadian clock genes expression in cancers: a meta-analysis of its association with clinicopathological features and prognosis[J]. PLoS One, 2020, 15(5): e0233508. DOI: 10.1371/journal.pone.0233508.
[11]	Zhang Z, Sun D, Tang H, et al. PER2 binding to HSP90 enhances immune response against oral squamous cell carcinoma by inhibiting IKK/NF-κB pathway and PD-L1 expression[J]. J Immunother Cancer, 2023, 11(11): e007627. DOI: 10.1136/jitc-2023-007627.
[12]	Yin S, Zhang Z, Tang H, et al. The biological clock gene PER1 affects the development of oral squamous cell carcinoma by altering the circadian rhythms of cell proliferation and apoptosis[J]. Chronobiol Int, 2022, 39(9): 1206-1219. DOI: 10.1080/07420528.2022.2082302.
[13]	Yang Y, Tang H, Zheng J, et al. The PER1/HIF-1alpha negative feedback loop promotes ferroptosis and inhibits tumor progression in oral squamous cell carcinoma[J]. Transl Oncol, 2022, 18: 101360. DOI: 10.1016/j.tranon.2022.101360.
[14]	Yang G, Yang Y, Tang H, et al. Loss of the clock gene Per1 promotes oral squamous cell carcinoma progression via the AKT/mTOR pathway[J]. Cancer Sci, 2020, 111(5): 1542-1554. DOI: 10.1111/cas.14362.
[15]	Zhang C, Dang D, Wang H, et al. Acircadian rhythm-related gene signature for predicting survival and drug response in HNSC[J]. Front Immunol, 2022, 13: 1029676. DOI: 10.3389/fimmu.2022.1029676.
[16]	Tampakakis E, Gangrade H, Glavaris S, et al. Heart neurons use clock genes to control myocyte proliferation[J]. Sci Adv, 2021, 7(49): eabh4181. DOI: 10.1126/sciadv.abh4181.
[17]	Gao Y, Wu Y, Zhang N, et al. IDH1 gene mutation activates Smad signaling molecules to regulate the expression levels of cell cycle and biological rhythm genes in human glioma U87-MG cells[J]. Mol Med Rep, 2021, 23(5): 354. DOI: 10.3892/mmr.2021.11993.
[18]	Pourali G, Ahmadzade AM, Arastonejad M, et al. The circadian clock as a potential biomarker and therapeutic target in pancreatic cancer[J]. Mol Cell Biochem, 2024, 479(5): 1243-1255. DOI: 10.1007/s11010-023-04790-4.
[19]	Hou L, Li H, Wang H, et al. The circadian clock gene PER2 enhances chemotherapeutic efficacy in nasopharyngeal carcinoma when combined with a targeted nanosystem[J]. J Mater Chem B, 2020, 8(24): 5336-5350. DOI: 10.1039/d0tb00595a. pmid: 32458942
[20]	Gil-Martín E, Ramos E, López-Muñoz F, et al. Potential of melatonin to reverse epigenetic aberrations in oral cancer: new findings[J]. EXCLI J, 2023, 22: 1280-1310. DOI: 10.17179/excli2023-6624. pmid: 38234969
[21]	Rahman S, Kraljević Pavelić S, Markova-Car E. Circadian (De) regulation in head and neck squamous cell carcinoma[J]. Int J Mol Sci, 2019, 20(11): 2662. DOI: 10.3390/ijms20112662.
[22]	Liu H, Gong X, Yang K. Overexpression of the clock gene Per2 suppresses oral squamous cell carcinoma progression by activating autophagy via the PI3K/AKT/mTOR pathway[J]. J Cancer, 2020, 11(12): 3655-3666. DOI: 10.7150/jca.42771. pmid: 32284762
[23]	Xiong H, Yang Y, Yang K, et al. Loss of the clock gene PER2 is associated with cancer development and altered expression of important tumor-related genes in oral cancer[J]. Int J Oncol, 2018, 52(1): 279-287. DOI: 10.3892/ijo.2017.4180. pmid: 29115399
[24]	Long W, Gong X, Yang Y, et al. Downregulation of PER2 promotes tumor progression by enhancing glycolysis via the phosphatidylinositol 3-kinase/protein kinase B pathway in oral squamous cell carcinoma[J]. J Oral Maxillofac Surg, 2020, 78(10): 1780. e1-1780.e14. DOI: 10.1016/j.joms.2020.05.035.
[25]	Li M, Sun D, Song N, et al. Mutant p53 in head and neck squamous cell carcinoma: molecular mechanism of gain-of-function and targeting therapy (review)[J]. Oncol Rep, 2023, 50(3): 162. DOI: 10.3892/or.2023.8599.
[26]	Cavga AD, Tardu M, Korkmaz T, et al. Cryptochrome deletion in p53 mutant mice enhances apoptotic and anti-tumorigenic responses to UV damage at the transcriptome level[J]. Funct Integr Genomics, 2019, 19(5): 729-742. DOI: 10.1007/s10142-019-00680-5.
[27]	Hou W, Hou W, Zhao X. Exploring transcriptomic databases: unraveling circadian gene disruptions in lower grade glioma[J]. Sci Rep, 2024, 14(1): 16960. DOI: 10.1038/s41598-024-67559-9. pmid: 39043735
[28]	Bieuville M, Dujon AM, Raven N, et al. When do tumours develop? Neoplastic processes across different timescales: age, season and round the circadian clock[J]. Evol Appl, 2024, 17(10): e70024. DOI: 10.1111/eva.70024.
[29]	Jin Y, Wang Z, Huang S, et al. Identify and validate circadian regulators as potential prognostic markers and immune infiltrates in head and neck squamous cell carcinoma[J]. Sci Rep, 2023, 13(1): 19939. DOI: 10.1038/s41598-023-46560-8.
[30]	Ao Y, Zhao Q, Yang K, et al. A role for the clock period circadian regulator 2 gene in regulating the clock gene network in human oral squamous cell carcinoma cells[J]. Oncol Lett, 2018, 15(4): 4185-4192. DOI: 10.3892/ol.2018.7825. pmid: 29541184
[31]	Carron J, Torricelli C, Silva JK, et al. microRNAs deregulation in head and neck squamous cell carcinoma[J]. Head Neck, 2021, 43(2): 645-667. DOI: 10.1002/hed.26533.
[32]	Zhao X, Zhu X, Cheng S, et al. MiR-29a/b/c regulate human circadian gene hPER1 expression by targeting its 3'UTR[J]. Acta Biochim Biophys Sin (Shanghai), 2014, 46(4): 313-317. DOI: 10.1093/abbs/gmu007.
[33]	Guo F, Tang Q, Chen G, et al. Aberrant expression and subcellular localization of PER2 promote the progression of oral squamous cell carcinoma[J]. Biomed Res Int, 2020, 2020: 8587458. DOI: 10.1155/2020/8587458.
[34]	Deng F, Yang K. Current status of research on the period family of clock genes in the occurrence and development of cancer[J]. J Cancer, 2019, 10(5): 1117-1123. DOI: 10.7150/jca.29212. pmid: 30854119
[35]	Shaashua L, Mayer S, Lior C, et al. Stromal expression of the core clock gene period 2 is essential for tumor initiation and metastatic colonization[J]. Front Cell Dev Biol, 2020, 8: 587697. DOI: 10.3389/fcell.2020.587697.
[36]	Chen M, Zhang L, Liu X, et al. PER1 is a prognostic biomarker and correlated with immune infiltrates in ovarian cancer[J]. Front Genet, 2021, 12: 697471. DOI: 10.3389/fgene.2021.697471.
[37]	Liu S, Cheng Y, Wang S, et al. Circadian clock genes modulate immune, cell cycle and apoptosis in the diagnosis and prognosis of pan-renal cell carcinoma[J]. Front Mol Biosci, 2021, 8: 747629. DOI: 10.3389/fmolb.2021.747629.
[38]	Lee Y, Field JM, Sehgal A. Circadian rhythms, disease and chronotherapy[J]. J Biol Rhythms, 2021, 36(6): 503-531. DOI: 10.1177/07487304211044301.
[39]	Santoni M, Molina-Cerrillo J, Santoni G, et al. Role of clock genes and circadian rhythm in renal cell carcinoma: recent evidence and therapeutic consequences[J]. Cancers (Basel), 2023, 15(2): 408. DOI: 10.3390/cancers15020408.
[40]	Zeng Y, Guo Z, Wu M, et al. Circadian rhythm regulates the function of immune cells and participates in the development of tumors[J]. Cell Death Discov, 2024, 10(1): 199. DOI: 10.1038/s41420-024-01960-1. pmid: 38678017
[41]	Tang Q, Xie M, Yu S, et al. Periodic oxaliplatin administration in synergy with PER2-mediated PCNA transcription repression promotes chronochemotherapeutic efficacy of OSCC[J]. Adv Sci (Weinh), 2019, 6(21): 1900667.
[42]	陈欣祎, 翁一鸣, 魏家燕, 等. 免疫检查点抑制剂在复发或转移性头颈部鳞状细胞癌治疗中的进展[J]. 国际肿瘤学杂志, 2023, 50(9): 553-557. DOI: 10.3760/cma.j.cn371439-20230410-00106.
[43]	Wu Y, Tao B, Zhang T, et al. Pan-cancer analysis reveals disrupted circadian clock associates with T cell exhaustion[J]. Front Immunol, 2019, 10: 2451. DOI: 10.3389/fimmu.2019.02451. pmid: 31708917

时钟基因Period家族在头颈鳞状细胞癌中的研究进展

Research progress of clock gene Period family in head and neck squamous cell carcinoma

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 43

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨胜军, 任江, 杨丹, 龙宇, 商群献. 非小细胞肺癌组织中miR-4262、NRG1的表达水平及临床意义[J]. 国际肿瘤学杂志, 2025, 52(3): 129-135.
[2]	王逸, 王强力, 张甲, 杨懿瑾, 王盛. 结直肠癌肝转移患者组织中SUCNR1和YBX1的表达与临床病理特征及预后的关系[J]. 国际肿瘤学杂志, 2025, 52(3): 152-157.
[3]	韩涛, 贾沛沛, 鲁静. iRhom1、iRhom2、TNF-α水平对宫颈癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2025, 52(3): 158-162.
[4]	王熙博, 田宝文, 陈士巧. Breg细胞在肿瘤免疫逃逸中的机制及相关治疗靶点[J]. 国际肿瘤学杂志, 2025, 52(2): 107-112.
[5]	陈丹蕾, 邓隽军, 李淼. 循环肿瘤细胞在肺癌中的临床应用进展[J]. 国际肿瘤学杂志, 2025, 52(2): 119-123.
[6]	姬海涛, 王延峰, 刘永成, 郝楠. 基于生物信息学分析DHCR7在胃癌中的表达及临床意义[J]. 国际肿瘤学杂志, 2025, 52(2): 94-100.
[7]	余洋, 唐仕敏, 杨露, 李娜. pT_2-3N₀M₀期胸段食管鳞状细胞癌治疗策略及预后影响因素研究进展[J]. 国际肿瘤学杂志, 2025, 52(1): 43-47.
[8]	黄镇, 晏菲, 马燕凌, 孙建海. 食管癌靶向及免疫治疗研究进展[J]. 国际肿瘤学杂志, 2025, 52(1): 53-59.
[9]	袁胜芳, 任婕, 林卫佳, 姬泽萱, 张长洪, 王布. EGFR共突变状态对晚期肺腺癌患者预后的价值研究[J]. 国际肿瘤学杂志, 2024, 51(9): 556-562.
[10]	伍杨, 李甜, 张润兵, 史婷婷, 高春, 郑晓凤, 张久聪. 胃癌及食管胃结合部癌免疫及靶向治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(9): 595-600.
[11]	詹海峰, 王文学, 耿嘉蔚. 晚期结直肠癌精准分子靶向治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(9): 601-605.
[12]	倪国英, 黄骞, 梁洪享, 杨志勇, 丁颖丽. 晚期非小细胞肺癌患者血清miR-499、miR-362水平变化及与预后的关系分析[J]. 国际肿瘤学杂志, 2024, 51(8): 487-492.
[13]	孟珂心, 陆海军. 口腔菌群：口腔鳞状细胞癌诊断和预后的生物标志物[J]. 国际肿瘤学杂志, 2024, 51(8): 515-519.
[14]	刘晶, 张俊. 放射性碘难治性分化型甲状腺癌再分化治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(7): 464-467.
[15]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.